Liquidia Technologies
Liquidia Corporation is a biopharmaceutical company dedicated to developing innovative therapies for patients with rare cardiopulmonary diseases. Their mission is to help patients breathe easier and live longer by enhancing drug delivery to the lungs, focusing on pulmonary hypertension and applications of their proprietary PRINT® Technology. They develop and commercialize products like YUTREPIA™ (treprostinil) inhalation powder for PAH and PH-ILD, and are working on investigational formulations such as L606. The company also markets generic Treprostinil Injection in partnership with Sandoz, Inc.
Industries
Nr. of Employees
medium (51-250)
Liquidia Technologies
Patents
Nanostructured surfaces for biomedical/biomaterial applications and processes thereof
US-9314548-B2
View Details
Nanostructured surfaces for biomedical/biomaterial applications and processes thereof
US-9314548-B2
View DetailsProducts
Treprostinil inhalation powder (dry powder formulation)
A dry powder inhalation formulation of treprostinil developed to deliver drug to deep lung tissues for treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Sustained-release treprostinil formulation for nebulizer (investigational)
An investigational twice-daily sustained-release formulation of treprostinil designed for administration with a next-generation nebulizer to provide extended pulmonary exposure.
Generic treprostinil injection (commercialized via partnership)
A generic injectable formulation of treprostinil marketed through a commercial partnership to treat pulmonary arterial hypertension.
YUTREPIA™ (treprostinil) inhalation powder
YUTREPIA is an FDA-approved, inhaled dry-powder formulation of treprostinil indicated for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
L606
A novel investigational inhaled sustained-release formulation of nanosized, liposomal treprostinil designed to prolong lung retention for the treatment of pulmonary arterial hypertension or pulmonary hypertension associated with interstitial lung disease.
Treprostinil Injection
Treprostinil Injection is a fully substitutable AP-rated generic formulation of Remodulin® (treprostinil) Injection, promoted in conjunction with commercial partner Sandoz, Inc.
Treprostinil inhalation powder (dry powder formulation)
A dry powder inhalation formulation of treprostinil developed to deliver drug to deep lung tissues for treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Sustained-release treprostinil formulation for nebulizer (investigational)
An investigational twice-daily sustained-release formulation of treprostinil designed for administration with a next-generation nebulizer to provide extended pulmonary exposure.
Generic treprostinil injection (commercialized via partnership)
A generic injectable formulation of treprostinil marketed through a commercial partnership to treat pulmonary arterial hypertension.
YUTREPIA™ (treprostinil) inhalation powder
YUTREPIA is an FDA-approved, inhaled dry-powder formulation of treprostinil indicated for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
L606
A novel investigational inhaled sustained-release formulation of nanosized, liposomal treprostinil designed to prolong lung retention for the treatment of pulmonary arterial hypertension or pulmonary hypertension associated with interstitial lung disease.
Treprostinil Injection
Treprostinil Injection is a fully substitutable AP-rated generic formulation of Remodulin® (treprostinil) Injection, promoted in conjunction with commercial partner Sandoz, Inc.
Services
End-to-end development of inhalation formulations including particle engineering, formulation optimization, and device integration for pulmonary delivery.
Protocol design, trial conduct and clinical program management for pulmonary hypertension studies including pivotal and cohort trials.
Operational manufacturing capabilities including process development, scale-up, transfer and validation to support clinical and commercial supply.
Preparation and management of regulatory filings, responses, and interactions with regulatory authorities to support approvals.
Commercial strategy, market access planning, and partnership execution to bring specialty pulmonary products to market.
End-to-end development of inhalation formulations including particle engineering, formulation optimization, and device integration for pulmonary delivery.
Protocol design, trial conduct and clinical program management for pulmonary hypertension studies including pivotal and cohort trials.
Operational manufacturing capabilities including process development, scale-up, transfer and validation to support clinical and commercial supply.
Preparation and management of regulatory filings, responses, and interactions with regulatory authorities to support approvals.
Commercial strategy, market access planning, and partnership execution to bring specialty pulmonary products to market.
Expertise Areas
- Inhaled drug delivery development
- Drug-device combination products
- Clinical trial management for pulmonary indications
- Formulation development (dry powder and sustained-release)
Key Technologies
- Particle engineering for pulmonary delivery
- Dry powder inhalation formulations
- Sustained-release formulations for nebulized delivery
- Next-generation nebulizer platforms
News & Updates
Upcoming event on June 4, 2025, at 11:05 AM EDT.
Event on May 27, 2025, at 8:30 AM EDT, discussing FDA approval of YUTREPIA.
Event on May 13, 2025, at 4:40 PM EDT.
Event on May 8, 2025, at 8:30 AM EDT.
FDA’s approval of YUTREPIA provides a new treatment option for patients with PAH and PH-ILD, designed for deep-lung delivery with an easy-to-use device.
New litigation filed against Liquidia alleges patent infringement and seeks to enjoin the company from commercializing YUTREPIA.
Upcoming event on June 4, 2025, at 11:05 AM EDT.
Event on May 27, 2025, at 8:30 AM EDT, discussing FDA approval of YUTREPIA.
Event on May 13, 2025, at 4:40 PM EDT.
Event on May 8, 2025, at 8:30 AM EDT.
FDA’s approval of YUTREPIA provides a new treatment option for patients with PAH and PH-ILD, designed for deep-lung delivery with an easy-to-use device.
New litigation filed against Liquidia alleges patent infringement and seeks to enjoin the company from commercializing YUTREPIA.